Hancock Jaffe Sells $41.4M In Stock To Fund Venous Therapies
The new public offering will fund the US pivotal trial of the company’s VenoValve device to treat chronic deep venous insufficiency in the legs.
The new public offering will fund the US pivotal trial of the company’s VenoValve device to treat chronic deep venous insufficiency in the legs.